pmed.1003038.g008.tif (1.58 MB)
Summary of response rates and magnitudes to vaccine-matched TV1c8.2.C and tier 1A MW965.26.C among per-protocol vaccine recipients of HVTN 100.
figure
posted on 2020-02-24, 18:24 authored by Fatima Laher, Zoe Moodie, Kristen W. Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L. Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B. Gilbert, Sanjay Phogat, Carlos A. DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N. Mkhize, Michael N. Pensiero, Vijay L. Mehra, James G. Kublin, Lawrence Corey, David C. Montefiori, Glenda E. Gray, M. Juliana McElrath, Georgia D. TomarasResponses to (A) TV1c8.2.C and (B) MW965.26.C. Bar charts show response rates with 2-sided 95% CIs. Boxplots show response magnitude as the ID50 neutralizing antibody titer and are based on positive responders, shown as solid blue circles; negative responders are shown as grey triangles. Grey lines connect the response magnitude of each per-protocol vaccine recipient over time. M[number], month [number]; vac, vaccination.
History
Usage metrics
Categories
Keywords
9 February 2015HIV subtype C pox-protein vaccine regimenstudy productsage 23 yearsZM 96.C gp 120subtype C pox-protein vaccinesIgG binding antibodyIgG bAb breadth scoresCD 40 ligandHIV prevention efficacyV 1V antigensTrial registration ClinicalTrials.gov NCT 024043111.CNational Clinical Trials RegistryRVZM 96.C V 1V12- month boosterDOH6- month vaccination3 vaccine-matched antigenspeak timepointsmonth 6.52 weeksIgG 3 bindingmonth 18vaccine-matched gp 120 antigensIgG 3 bAb responsesmonth 12CIHVTNSANCTRALVAC-HIV26 May 2015. Vaccine recipients
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC